The company expects revenue to grow in the mid to high single digits in FY26 but has not offered specific margin guidance for the year.

The company projects revenue growth of mid- to high single digits in FY26 compared with an 8.5% increase in FY25 ...

Sun Pharma will invest up to $25 million in US-based Pharmazz Inc, raising its stake to 22.7%. The deal strengthens Sun’s ...

India’s largest drugmaker plans a $100 million push into US specialty drugs in FY26, even as it braces for regulatory ...

Dystrophic epidermolysis bullosa (DEB) is one of the main subtypes of epidermolysis bullosa, a group of genetic skin disorders characterized by varying degrees of fragility in the skin and mucous ...

Clear signs of immune activation: ICT01 at the 10 mg dose provided optimal activation of γ9δ2 T cells and a downstream immune ...

Novita Pharmaceuticals, Inc. ("Novita"), a privately held, clinical-stage pharmaceutical company dedicated to developing novel cancer drugs through its proprietary fascin inhibitor technology, today ...

ATG-037, an oral small molecule CD73 inhibitor, in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), ...

Genmab A/S (Nasdaq: GMAB) announced today that it will present new research from its comprehensive development program evaluating its late-stage portfolio at the 2025 American Society of Clinical ...

GV20 Therapeutics (GV20), a clinical-stage AI-powered biotherapeutics company, today announced that Dr. Kristopher Wentzel ...

Vertex Pharmaceuticals has solid revenue projections for its CF franchise, and a promising drug pipeline, especially in pain.